FLQL vs IVZ

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 51 cases where FLQL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for FLQL just turned positive on November 12, 2026. Looking at past instances where FLQL's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.

Following a +3.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where FLQL advanced for three days, in 287 of 348 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

FLQL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FLQL as a result. In 60 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.

FLQL moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for FLQL crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FLQL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.

The Aroon Indicator for FLQL entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IVZ's RSI Oscillator exited the oversold zone, 20 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.

The Moving Average Convergence Divergence (MACD) for IVZ just turned positive on November 09, 2026. Looking at past instances where IVZ's MACD turned positive, the stock continued to rise in 32 of 45 cases over the following month. The odds of a continued upward trend are 71%.

Following a +6.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVZ advanced for three days, in 227 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

IVZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IVZ as a result. In 58 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.

The Aroon Indicator for IVZ entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. IVZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 53 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock slightly better than average.

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.200) is normal, around the industry mean (2.423). IVZ has a moderately low P/E Ratio (-40.418) as compared to the industry average of (8.341). Projected Growth (PEG Ratio) (0.901) is also within normal values, averaging (1.318). Dividend Yield (0.032) settles around the average of (0.274) among similar stocks. P/S Ratio (1.981) is also within normal values, averaging (15.906).

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.